Compare HP Inc (HPQ) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HP Inc vs GeneDx Holdings Corp — how do they compare? HP Inc trades at $30.2 (market cap $29.25B), while GeneDx Holdings Corp trades at $67.33 (market cap $2.02B). The key difference: HP Inc is far larger — about 14.5× GeneDx Holdings Corp's market cap, and HP Inc pays a 3.7% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold HP Inc for 69 Days and GeneDx Holdings Corp for 19 Days on average.
| HPQ | WGS | |
|---|---|---|
Market Cap | $29.25B | $2.02B |
Volume | 10,025,806 | 734,640 |
Sector | Technology | Health |
52-Week High | $35.48 | $167.51 |
52-Week Low | $18.20 | $34.51 |
Typical Hold Time | 69 Days | 19 Days |
Enterprise Value | $35.42B | $2.05B |
Dividend Yield | 3.7% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HPQ trades at $32.44, up 0.62% today, with a bullish technical signal from moving averages. The stock has beaten earnings estimates for three consecutive quarters, with Q3 2026 results pending. Revenue is projected to grow to $59.2B in 2026, though net margins are compressing. Recent news highlights HP's new AI-ready PCs but also a cautious outlook for 2027 PC sales.
The outlook is mixed: valuation appears reasonable with a P/E of 12.38, but declining PC demand poses a headwind. Analyst consensus is cautious with a hold-heavy rating, though the stock offers a 3.82% dividend yield. Key risks include execution in a competitive hardware market and macroeconomic sensitivity.
GeneDx (WGS) trades at $67.73, down 1.17% with bearish technical signals despite recent earnings beats. The company shows strong revenue growth to $454M in 2026 but faces profitability challenges with a -23.4% net margin. Recent developments include new genomic testing products and hospital partnerships, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth story with expanding genomic testing volumes but carries significant execution risk given negative profitability metrics. Upside potential exists if management can translate revenue growth into sustainable profits, though current cash flow trends and high valuation multiples warrant caution for risk-averse investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About HP Inc
HP Incorporated is a leading provider of computers, printers, and printer supplies. The company's mains segments are personal systems and printing. Its personal systems segment contains notebooks, desktops, and workstations. Its printing segment contains supplies, consumer hardware, and commercial hardware. In 2015, Hewlett-Packard was separated into HP Incorporated and Hewlett Packard Enterprise and the Palo Alto, California-based HP Incorporated sells on a global scale.
Read more on HPQ →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
